Cargando…

Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review

BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is associated with significant morbidity and mortality. Bedaquiline is the first drug approved for treating MDR-TB. OBJECTIVES: We performed a systematic review and meta-analysis to summarize the totality of all available evidence on the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Charan, Jaykaran, Reljic, Tea, Kumar, Ambuj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825437/ https://www.ncbi.nlm.nih.gov/pubmed/27127322 http://dx.doi.org/10.4103/0253-7613.178839

Ejemplares similares

Author Reply
por: Charan, Jaykaran, et al.
Publicado: (2016)

Comparison of methodological quality of positive versus negative comparative studies published in Indian medical journals: a systematic review
por: Charan, Jaykaran, et al.
Publicado: (2015)

Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis
por: Charan, Jaykaran, et al.
Publicado: (2019)

Bedaquiline versus placebo for management of multidrug-resistant tuberculosis: A systematic review
por: Singh, Surjit, et al.
Publicado: (2016)

Relationship between clinical trials and disease burden of India: A cross-sectional study
por: Kaur, Rimplejeet, et al.
Publicado: (2020)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review
por: Singh, Lisa, et al.
Publicado: (2021)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review
por: Reljic, Tea, et al.
Publicado: (2017)

Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis
por: Wang, Ming-Gui, et al.
Publicado: (2021)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
por: Wu, Sheng-Han, et al.
Publicado: (2021)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin
por: Khoza-Shangase, Katijah, et al.
Publicado: (2021)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug
por: Jain, Nirmal Kumar
Publicado: (2022)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
por: Kharfan-Dabaja, Mohamed A, et al.
Publicado: (2013)

In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates
por: Degiacomi, Giulia, et al.
Publicado: (2020)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis
por: Walsh, Kathleen F, et al.
Publicado: (2022)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid
por: Nieto Ramirez, Luisa Maria, et al.
Publicado: (2020)

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
por: Starshinova, Anna, et al.
Publicado: (2022)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
por: Fox, Gregory J., et al.
Publicado: (2013)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Emergence of bedaquiline resistance in a high tuberculosis burden country
por: Chesov, Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5olqsegg9hadba2cquk8odcdtb